Cancer clinical trials in the region Auvergne-Rhône-Alpes

488 currently recruiting clinical trials
Region Auvergne-Rhône-Alpes

Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Required histologic sub types
Neuroendocrine carcinoma
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
7 recruiting sites
UNICANCER
Phase 2 Lung cancer #NCT07221474 #2025-520902-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05980806 #2024-511309-47-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
8 recruiting sites
Karyopharm Therapeutics Inc.
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05037760 #2023-507468-38-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05037760 #2023-507468-38-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
2 recruiting sites
Takeda
Phase 2 Prostate cancer #NCT07287150 #2025-521327-67-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
2 recruiting sites
Hoffmann-La Roche
Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06172478 #2023-507641-29-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2 Lung cancer #NCT06393816 #2023-506590-35-00
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Large-cell neuroendocrine carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
7 recruiting sites
Centre Léon Bérard
Phase 2 Colon cancer Rectal cancer Anal cancer #NCT04954820
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
1
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
26 recruiting sites
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Pancreas cancer Stomach and esophageal cancer #NCT04325425 #2024-515300-39-00
Required histologic types
Stomach
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
14 recruiting sites
CHU Dijon